# Baricitinib for the Lung Injury Following Spontaneous SAH

> **NCT06439615** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Spontaneous Subarachnoid Hemorrhage

## Interventions

- **DRUG:** Baricitinib 4 MG
- **OTHER:** Standard treatment

## Key facts

- **NCT ID:** NCT06439615
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06439615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06439615, "Baricitinib for the Lung Injury Following Spontaneous SAH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06439615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*